On July 28, Baxter rose 5.01% in regular trading, trading at $24.5/share, with turnover of $36.34 million. The rally was driven by Stifel significantly raising its price target on Baxter from $19 to $24, while maintaining a Hold rating.

Notably, Stifel's upgrade is part of a broader wave of analyst optimism. Goldman Sachs raised its target from $19 to $21 on July 14, while Evercore ISI lifted its target from $22 to $24 in early July. The current FactSet consensus mean price target stands at $21, suggesting the stock is now trading above average analyst expectations. This concentrated series of upward revisions reflects improving sentiment around Baxter's outlook heading into its next earnings release on July 30.

For context, Baxter reported Q1 adjusted EPS of $0.37 in late April, beating the $0.31 estimate, and issued full-year guidance of $1.85-$2.05 adjusted EPS. The company also recently restructured its segment reporting by integrating its Pharmaceuticals unit into the Infusion Therapies and Platform division, a move aimed at enhancing operational synergies.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)